Report Detail
Tissue Regenerative Materials - Medical Devices Pipeline Assessment, 2020
- RnM4099031 |
- 15 July, 2020 |
- Global |
- 63 Pages |
- GlobalData |
- Other
Tissue Regenerative Materials - Medical Devices Pipeline Assessment, 2020
Summary
GlobalData's Medical Devices sector report, “Tissue Regenerative Materials - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Tissue Regenerative Materials pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. Tissue Regenerative Materials is a biomaterial component which facilitates regeneration of lost periodontal hard and soft tissue.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
- Extensive coverage of the Tissue Regenerative Materials under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Tissue Regenerative Materials and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry
Reasons to Buy
The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Tissue Regenerative Materials under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date
1 Table of Contents
- 1.1 List of Tables
- 1.2 List of Figures
2 Introduction
- 2.1 Tissue Regenerative Materials Overview
3 Products under Development
- 3.1 Tissue Regenerative Materials - Pipeline Products by Stage of Development
- 3.2 Tissue Regenerative Materials - Pipeline Products by Territory
- 3.3 Tissue Regenerative Materials - Pipeline Products by Regulatory Path
- 3.4 Tissue Regenerative Materials - Pipeline Products by Estimated Approval Date
- 3.5 Tissue Regenerative Materials - Ongoing Clinical Trials
4 Tissue Regenerative Materials - Pipeline Products under Development by Companies
- 4.1 Tissue Regenerative Materials Companies - Pipeline Products by Stage of Development
- 4.2 Tissue Regenerative Materials - Pipeline Products by Stage of Development
5 Tissue Regenerative Materials Companies and Product Overview
- 5.1 Biora AB Company Overview
- 5.1.1 Biora AB Pipeline Products & Ongoing Clinical Trials Overview
- 5.2 Collagen Matrix Inc Company Overview
- 5.2.1 Collagen Matrix Inc Pipeline Products & Ongoing Clinical Trials Overview
- 5.3 Colorado Therapeutics, LLC Company Overview
- 5.3.1 Colorado Therapeutics, LLC Pipeline Products & Ongoing Clinical Trials Overview
- 5.4 credentis AG Company Overview
- 5.4.1 credentis AG Pipeline Products & Ongoing Clinical Trials Overview
- 5.5 Gene Techno Science Co Ltd Company Overview
- 5.5.1 Gene Techno Science Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
- 5.6 Histocell SL Company Overview
- 5.6.1 Histocell SL Pipeline Products & Ongoing Clinical Trials Overview
- 5.7 Indian Institute of Technology Bombay Company Overview
- 5.7.1 Indian Institute of Technology Bombay Pipeline Products & Ongoing Clinical Trials Overview
- 5.8 LaunchPad Medical, LLC Company Overview
- 5.8.1 LaunchPad Medical, LLC Pipeline Products & Ongoing Clinical Trials Overview
- 5.9 Maxigen Biotech Inc Company Overview
- 5.9.1 Maxigen Biotech Inc Pipeline Products & Ongoing Clinical Trials Overview
- 5.1 Nobel Biocare Services AG Company Overview
- 5.10.1 Nobel Biocare Services AG Pipeline Products & Ongoing Clinical Trials Overview
- 5.11 Novatissue SAS Company Overview
- 5.11.1 Novatissue SAS Pipeline Products & Ongoing Clinical Trials Overview
- 5.12 Orthocell Ltd Company Overview
- 5.12.1 Orthocell Ltd Pipeline Products & Ongoing Clinical Trials Overview
- 5.13 Polytechnic University of Catalonia Company Overview
- 5.13.1 Polytechnic University of Catalonia Pipeline Products & Ongoing Clinical Trials Overview
- 5.14 Straumann Holding AG Company Overview
- 5.14.1 Straumann Holding AG Pipeline Products & Ongoing Clinical Trials Overview
- 5.15 SurgaColl Technologies Ltd Company Overview
- 5.15.1 SurgaColl Technologies Ltd Pipeline Products & Ongoing Clinical Trials Overview
- 5.16 SweetBio, Inc. Company Overview
- 5.16.1 SweetBio, Inc. Pipeline Products & Ongoing Clinical Trials Overview
- 5.17 Tigran Technologies AB Company Overview
- 5.17.1 Tigran Technologies AB Pipeline Products & Ongoing Clinical Trials Overview
- 5.18 Trimph Technology Pty Ltd Company Overview
- 5.18.1 Trimph Technology Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview
6 Tissue Regenerative Materials- Recent Developments
- 6.1 Feb 18, 2020: Straumann finishes 2019 with solid Q4, as full-year organic revenue climbs 17% and core EBIT margin expands to 27.1%
- 6.2 Feb 14, 2020: CollPlant Biotechnologies raising $4.45 million in U.S. Private Placement
- 6.3 Feb 10, 2020: CollPlant announces appointment of Roger J. Pomerantz, M.D., F.A.C.P. as Chairman of the Board of Directors
- 6.4 Feb 05, 2020: Orthocell receives new patents for CelGro platform
- 6.5 Feb 03, 2020: Mark Johnson joins Straumann’s Executive Management as Head of Research, Development & Operations, succeeding Dr Gerhard Bauer, who is retiring after a distinguished career with the Group
- 6.6 Dec 06, 2019: Straumann Group strengthens emphasis on orthodontics and digital transformation
- 6.7 Nov 29, 2019: CollPlant reports third quarter 2019 financial results and provides business update
- 6.8 Oct 22, 2019: CollPlant CEO Yehiel Tal appointed to serve on international society for Biofabrication's Industry Relations Committee
- 6.9 Sep 26, 2019: CollPlant reports second quarter 2019 financial results and provides business update
- 6.1 Aug 29, 2019: Straumann Group announces two appointments to its Executive Management team
- 6.11 Aug 14, 2019: Straumann Group: Strong momentum continues as first-half organic revenue climbs 16% and core EBIT margin reaches 28%
7 Appendix
- 7.1 Methodology
- 7.2 About GlobalData
Summary:
Get latest Market Research Reports on Tissue Regenerative Materials - Medical Devices Pipeline Assessment, 2020. Industry analysis & Market Report on Tissue Regenerative Materials - Medical Devices Pipeline Assessment, 2020 is a syndicated market report, published as Tissue Regenerative Materials - Medical Devices Pipeline Assessment, 2020. It is complete Research Study and Industry Analysis of Tissue Regenerative Materials - Medical Devices Pipeline Assessment, 2020 market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
